Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation

Metastatic prostate cancer is characterized by recurrent genomic copy number alterations that are presumed to contribute to resistance to hormone therapy. We identified CHD1 loss as a cause of antiandrogen resistance in an in vivo small hairpin RNA (shRNA) screen of 730 genes deleted in prostate can...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zeda, Zhou, Chuanli, Li, Xiaoling, Barnes, Spencer D., Deng, Su, Hoover, Elizabeth, Chen, Chi-Chao, Lee, Young Sun, Zhang, Yanxiao, Wang, Choushi, Metang, Lauren A., Wu, Chao, Tirado, Carla Rodriguez, Johnson, Nickolas A., Wongvipat, John, Navrazhina, Kristina, Cao, Zhen, Choi, Danielle, Huang, Chun-Hao, Linton, Eliot, Chen, Xiaoping, Liang, Yupu, Mason, Christopher E., de Stanchina, Elisa, Abida, Wassim, Lujambio, Amaia, Li, Sheng, Lowe, Scott W., Mendell, Joshua T., Malladi, Venkat S., Sawyers, Charles L., Mu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292228/
https://www.ncbi.nlm.nih.gov/pubmed/32220301
http://dx.doi.org/10.1016/j.ccell.2020.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292228/
https://www.ncbi.nlm.nih.gov/pubmed/32220301
http://dx.doi.org/10.1016/j.ccell.2020.03.001

Ejemplares similares